Published in J Clin Oncol on January 15, 2004
Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol (2015) 2.70
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol (2015) 2.42
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol (2010) 1.65
Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer (2007) 1.02
Update on management of seminoma. Indian J Urol (2010) 0.99
Current management of testicular cancer. Korean J Urol (2013) 0.98
Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer (2013) 0.95
Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol (2008) 0.93
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer (2013) 0.85
Testis cancer. Postgrad Med J (2007) 0.84
CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer (2007) 0.84
[Is cardiotoxicity still an issue after breast-conserving surgery and could it be reduced by multifield IMRT?]. Strahlenther Onkol (2009) 0.84
Radiotherapy in stage I seminoma of the testis. J Clin Oncol (2004) 0.81
Clinical stage I seminoma: the case for surveillance. World J Urol (2009) 0.81
Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. Asian J Androl (2015) 0.78
Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys (2011) 0.77
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor. Oncol Lett (2015) 0.77
Survival from testicular cancer in England and Wales up to 2001. Br J Cancer (2008) 0.77
Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma. Res Rep Urol (2015) 0.76
Stage IIA and IIB testicular seminoma treated postorchiectomy with radiation therapy versus other approaches: a population-based analysis of 241 patients. Int Braz J Urol (2015) 0.75
Advances in the treatment of testicular cancer. Transl Androl Urol (2015) 0.75
The sword of Damocles and the treatment of stage I seminoma. J Clin Oncol (2006) 0.75
Testicular cancer: Underestimating radiotherapy toxicity for stage I seminoma. Nat Rev Urol (2012) 0.75
Contemporary management of stage I testicular seminoma: a survey of Canadian radiation oncologists. Curr Oncol (2008) 0.75
Feasibility of low-dose CT with model-based iterative image reconstruction in follow-up of patients with testicular cancer. Eur J Radiol Open (2016) 0.75
Multiple secondary malignancies following radiation therapy for testicular cancer. Can Urol Assoc J (2015) 0.75
Long-term outcomes following post-operative radiotherapy for Stage I/II testicular seminoma - an Australasian single-institution experience. J Med Radiat Sci (2016) 0.75
Clinical outcomes in patients with stage I non-seminomatous germ cell cancer. Asian J Androl (2013) 0.75
Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship. Acta Oncol (2015) 0.75
Platinum-based Chemotherapy in Primary Advanced Seminoma-a Retrospective Analysis: Treatment Results at the Northern Israel Oncology Center (1989-2010). Rambam Maimonides Med J (2014) 0.75
Radiotherapy for Stage IIA seminoma: The Northern Israel Oncology Center Experience, 1971-2010. Rep Pract Oncol Radiother (2014) 0.75
Treatment for PSA screen-detected prostate cancer: what are the options? Nat Clin Pract Urol (2009) 0.75
Treatment-related ureteral cancer following stage II testicular seminoma. Int J Clin Oncol (2007) 0.75
Current treatment options for clinical stage I seminoma. World J Urol (2009) 0.75
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 6.98
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood (2008) 4.41
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
The landscape of recombination in African Americans. Nature (2011) 3.06
Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent. Am J Public Health (2005) 2.94
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Birthplace, years of residence in the United States, and obesity among Mexican-American adults. Obesity (Silver Spring) (2007) 2.28
Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys (2009) 2.27
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer (2010) 2.17
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Angiosarcoma of the breast. Cancer (2005) 1.98
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck (2007) 1.73
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys (2010) 1.70
Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer (2002) 1.67
Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys (2006) 1.65
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood (2011) 1.58
Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys (2003) 1.57
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer. Phys Med Biol (2008) 1.51
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer (2013) 1.48
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J (2012) 1.47
Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst (2003) 1.42
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys (2007) 1.40
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood (2007) 1.32
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci (2012) 1.31
A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. Int J Radiat Oncol Biol Phys (2011) 1.31
Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.30
Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer (2004) 1.30
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood (2012) 1.26
Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet (2013) 1.24
Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer (2003) 1.24
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys (2010) 1.21
Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer (2006) 1.20
Patient-specific quality assurance for prostate cancer patients receiving spot scanning proton therapy using single-field uniform dose. Int J Radiat Oncol Biol Phys (2011) 1.19
A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol Biol Phys (2012) 1.19
Liposarcoma of the head and neck: The University of Texas M. D. Anderson Cancer Center experience. Head Neck (2009) 1.18
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.17
Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer (2006) 1.17
Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol (2009) 1.16
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology (2009) 1.15
Maternal BMI and country of birth as indicators of childhood obesity in children of Mexican origin. Obesity (Silver Spring) (2007) 1.15
Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer (2006) 1.15
Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.13
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res (2003) 1.13
Marijuana use and testicular germ cell tumors. Cancer (2010) 1.13
Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. Blood (2013) 1.12
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis (2006) 1.09
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.09
Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev (2010) 1.09
Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys (2003) 1.06
Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.06
Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.05
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol (2010) 1.05
An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 1.05
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys (2012) 1.04
Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol (2003) 1.04
Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys (2004) 1.03
The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol (2006) 1.02
Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res (2010) 1.02
The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer (2009) 1.02
Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys (2003) 1.01
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics (2006) 1.00
Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys (2008) 0.99
Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys (2009) 0.99
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res (2007) 0.99
Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg (2007) 0.98
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol (2006) 0.97
Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer (2014) 0.96
A case-control study of dietary phytoestrogens and testicular cancer risk. Nutr Cancer (2002) 0.96
An approach to the management of the patient with metastatic bone disease. Instr Course Lect (2004) 0.95
Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. Cancer (2002) 0.95
A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer (2011) 0.95
In vivo tumor imaging in mice with near-infrared labeled endostatin. Mol Cancer Ther (2004) 0.95
Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck (2008) 0.95
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol (2002) 0.94
Prenatal and perinatal risk factors and testicular cancer: a hospital-based case-control study. Oncol Res (2007) 0.94
Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys (2003) 0.93
Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2005) 0.93
Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol (2002) 0.93
Dosimetric changes resulting from patient rotational setup errors in proton therapy prostate plans. Int J Radiat Oncol Biol Phys (2008) 0.92
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst (2005) 0.92
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf (2011) 0.92
A 12-year experience using the Brown two-portal endoscopic procedure of transverse carpal ligament release in 14,722 patients: defining a new paradigm in the treatment of carpal tunnel syndrome. Plast Reconstr Surg (2007) 0.92